Patents by Inventor Eldon R. Jupe

Eldon R. Jupe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7273855
    Abstract: It has now been found that the introduction of single stranded oligonucleotides of DNA or RNA, particularly RNA transcribed from portions of wild type prohibitin 3?UTR, into tumors leads to arrested cell proliferation. Significant reduction in the size of primary tumors has been observed following direct administration of prohibitin 3?UTR RNA. Induction of systemic immunity, as evidenced by the disappearance of metastases as well as the lack of tumor growth in rechallenged animals following prohibitin RNA therapy, has been observed. Thus, wild type RNAs transcribed from portions of a prohibitin 3?UTR, or single stranded DNAs comprised of portions of a prohibitin 3?UTR, or synthetically-made oligonucleotides of the same sequences, can be directly administered as therapeutic agents against tumors.
    Type: Grant
    Filed: July 8, 2002
    Date of Patent: September 25, 2007
    Assignee: Oklahoma Medical Research Foundation
    Inventor: Eldon R. Jupe
  • Patent number: 7259251
    Abstract: The 3? untranslated region of the human prohibitin gene has been isolated for use in a cancer susceptibility screen and as a therapeutic agent for the treatment of cancer.
    Type: Grant
    Filed: June 7, 1996
    Date of Patent: August 21, 2007
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Robert T. Dell'Orco, Eldon R. Jupe, J. Keith McClung, Xiao-Tie Liu, Robert L. King
  • Patent number: 7094538
    Abstract: The lifetime probability of a person developing cancer can now be determined based on an allelic variation found in the 3?UTR of the prohibitin gene. The probability is dependent on the sequence of the 3?UTR at position 729, i.e., whether there is a thymine (T) or a cytosine (C) or both at this position. Determining the sequence at the position 729 can be done by any number of standard techniques. Preferably, the sequence is determined by amplifying this region by PCR and subjecting it to an RFLP analysis.
    Type: Grant
    Filed: June 10, 2002
    Date of Patent: August 22, 2006
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Eldon R. Jupe, Linda F. Thompson, Regina Resta, Robert T. Dell'Orco
  • Publication number: 20030171316
    Abstract: It has now been found that the introduction of single stranded oligonucleotides of DNA or RNA, particularly RNA transcribed from portions of wild type prohibitin 3′UTR, into tumors leads to arrested cell proliferation. Significant reduction in the size of primary tumors has been observed following direct administration of prohibitin 3′UTR RNA. Induction of systemic immunity, as evidenced by the disappearance of metastases as well as the lack of tumor growth in rechallenged animals following prohibitin RNA therapy, has been observed. Thus, wild type RNAs transcribed from portions of a prohibitin 3′UTR, or single stranded DNAs comprised of portions of a prohibitin 3′UTR, or synthetically-made oligonucleotides of the same sequences, can be directly administered as therapeutic agents against tumors.
    Type: Application
    Filed: July 8, 2002
    Publication date: September 11, 2003
    Applicant: Oklahoma Medical Research Foundation
    Inventor: Eldon R. Jupe
  • Publication number: 20030073107
    Abstract: The lifetime probability of a person developing cancer can now be determined based on an allelic variation found in the 3′UTR of the prohibitin gene. The probability is dependent on the sequence of the 3′UTR at position 729, i.e., whether there is a thymine (T) or a cytosine (C) or both at this position. Determining the sequence at the position 729 can be done by any number of standard techniques. Preferably, the sequence is determined by amplifying this region by PCR and subjecting it to an RFLP analysis.
    Type: Application
    Filed: June 10, 2002
    Publication date: April 17, 2003
    Applicant: Oklahoma Medical Research Foundation
    Inventors: Eldon R. Jupe, Linda F. Thompson, Regina Resta, Robert T. Dell'Orco
  • Patent number: 6355427
    Abstract: The lifetime probability of a woman developing breast cancer can now be determined based on an allelic variation found in the 3′UTR of the prohibitin gene. The probability is dependent on the sequence of the 3′UTR at position 729, i.e., whether there is a thymine (T) or a cytosine (C) or both at this position. Polymorphism at position 729 is also disclosed as a susceptibility indicator for hereditary breast cancer in men. Determining the sequence at the position 729 can be done by any number of standard techniques. Preferably, the sequence is determined by amplifying this region by PCR and subjecting it to an RFLP analysis.
    Type: Grant
    Filed: May 7, 1999
    Date of Patent: March 12, 2002
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Eldon R. Jupe, Linda F. Thompson, Regina Resta, Robert T. Dell'Orco